Showing 3551-3560 of 7376 results for "".
- Inaugural World Eczema Day: GlobalSkin Launches International Movement for Eczema Sufferershttps://practicaldermatology.com/news/inaugural-world-eczema-day-globalskin-launches-international-movement-for-eczema-sufferers/2457611/To mark the first-ever Atopic Eczema Day, the International Alliance of Dermatology Patient Organizations (IADPO – also known as GlobalSkin) has launched AltogetherEczema, a new movement to elevate the urgent and unmet needs of the global eczema and atopic dermatitis community.
- First-Ever Molecular Study Shows African American Skin Reacts Differently to ADhttps://practicaldermatology.com/news/first-ever-molecular-study-shows-african-american-skin-reacts-differently-to-ad/2457612/African Americans are known to have greater treatment challenges with atopic dermatitis than European Americans and require higher doses of some medications to get relief, and now a new study suggests that differences in the molecular profile of their skin may be the reason. About 19 perc
- New Laser Handpiece Clears Multicolor Tattoos in Fewer Treatmentshttps://practicaldermatology.com/news/new-laser-handpiece-clears-multicolor-tattoos-in-fewer-treatments/2457613/A new titanium sapphire laser handpiece can clear green, blue, and purple tattoo pigments in fewer treatments, according to a new study in Lasers in Surgery and Medicine (LSM). Researchers led by American Soc
- Foamix: Positive Topline Phase 3 Results for Topical Minocycline Foamhttps://practicaldermatology.com/news/foamix-positive-topline-phase-3-results-for-topical-minocycline-foam/2457614/Foamix Pharmaceuticals’ FMX101 topical minocycline foam for the treatment of moderate-to-severe acne has met primary endpoints of its third Phase 3 clinical trial. Foamix shared topline results of the clinical trial (FX2017-22), which met both co-prim
- Allergan Launches Spotlyte: Digital Hub Will Educate Consumers About Medical Aesthetic Treatmentshttps://practicaldermatology.com/news/allergan-launches-spotlyte/2457615/Allergan has launched Spotlyte, described as an innovative digital hub of curated content that helps consumers discover how medical aesthetic treatments may fit into their routines.
- Mayo Clinic Doctors Receive Stand Up to Cancer Catalyst Award for Melanoma Researchhttps://practicaldermatology.com/news/mayo-clinic-doctors-receive-stand-up-to-cancer-catalyst-award-for-melanoma-research/2457617/Mayo Clinic immunologist and medical oncologist Matthew Block, M.D., Ph.D. and surgeon Tina Hieken, M.D., received a
- Bee Venom May Help Treat Eczemahttps://practicaldermatology.com/news/bee-venom-may-help-treat-eczema/2457619/Bee venom and its major component, melittin, may be effective treatments for atopic dermatitis, according to a British Journal of Pharmacology study. Through studies conducted in mice and in human cells, inv
- Ekwa Marketing Launches Affiliate Program, Offers Residual Income Opportunity for Medical Associationshttps://practicaldermatology.com/news/ewa-marketing-launches-affiliate-program-offers-residual-income-opportunity-for-medical-associations/2457622/Ekwa Marketing has launched its unique Ekwa Affiliate Program. Medical associations can simply place an online link to Ekwa’s innovative digital marketing products for doctors on their website and social media networks, and start receiving a passive i
- New Skinder App May Help Med Students Spot Skin Cancerhttps://practicaldermatology.com/news/new-skinder-app-may-help-med-students-spot-skin-cancer/2457627/Skinder, a dermatologist-developed app, may help medical students learn to spot skin cancer. Skinder works like the matchmaking app Tinder. But instead of considering pictures of potential dates, swiping right if they’re attractive or left if they’re not, users consider high-r
- Psoriasis Myths, Stigmas Aboundhttps://practicaldermatology.com/news/myths-stigmas-about-psoriasis-abound/2457628/Stigmatizing views and myths about psoriasis are pervasive among the general population and medical students in the United States, according to multidisciplinary research from the Perelman School of Medicine at the University of Pennsylvania. The findings